GeNeuro

Switzerland
Hasle, Lucerne, Switzerland, 1228

Company profile

GeNeuro company profile

GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.

Business identity

Contact email
[email protected]
Phone number
+41227945085
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2006-01-01, Year

Headquarters

Postal code
1228
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
7
Total equity funding
$39.9M
Last funding
Post IPO Equity / $5.4M / 2024-02-01
Last equity funding
Post IPO Equity / $5.4M
Investors
6
Lead investors
2
Founders
1
Articles
65
Exited on
2016-04-15

Founders and investors

Founders

Jesús Martin-Garcia

Lead investors

European Investment BankFederal Office of Public Health (FOPH) Switzerland

Investors

European Investment BankFederal Office of Public Health (FOPH) SwitzerlandInstitut MerieuxInvescoServier